Detalhe da pesquisa
1.
Breast Cancer with HER2 IHC 2+ and Average HER2 Signals/Cell ≥ 6 and HER2/CEP17 Ratio < 2: A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype.
Mod Pathol
; : 100530, 2024 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38810729
2.
The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy.
Ann Surg Oncol
; 30(13): 8353-8361, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37658272
3.
MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients.
Genes Chromosomes Cancer
; 61(3): 148-160, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34841595
4.
BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance.
Breast Cancer Res Treat
; 195(3): 263-274, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35984580
5.
HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles.
Mod Pathol
; 35(8): 1075-1082, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35184150
6.
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.
Ann Surg Oncol
; 2022 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35378634
7.
High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancer.
J Surg Oncol
; 125(4): 596-602, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34964996
8.
MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial.
BMC Cancer
; 20(1): 81, 2020 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-32005181
9.
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Breast Cancer Res Treat
; 168(3): 625-630, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29275435
10.
Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.
Breast Cancer Res Treat
; 153(3): 607-16, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26346756
11.
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer.
Surg Oncol
; 45: 101885, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36436423
12.
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy.
JCO Precis Oncol
; 6: e2200197, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108259
13.
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.
JCO Precis Oncol
; 6: e2100463, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35476550
14.
Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study.
Clin Cancer Res
; 27(20): 5482-5491, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34301749
15.
Prospective Validation of a Genomic Assay in Breast Cancer: The 70-gene MammaPrint Assay and the MINDACT Trial.
Acta Med Acad
; 48(1): 18-34, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31264430
16.
Changing Landscape of Clinical-Genomic Oncology Practice.
Acta Med Acad
; 48(1): 6-17, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31264429
17.
Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers.
NPJ Breast Cancer
; 5: 15, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31016233
18.
Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.
JAMA Oncol
; 4(1): e173470, 2018 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29075751
19.
Reply to W. Altundag.
JCO Precis Oncol
; 6: e2200315, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35952323
20.
Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance.
Clin Breast Cancer
; 13(4): 223-32, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23829888